The Med­i­cines Com­pa­ny brings out the ax, look­ing to jet­ti­son hun­dreds of jobs in top-to-bot­tom re­struc­tur­ing

The Med­i­cines Com­pa­ny CEO Clive Mean­well is cir­cling all the wag­ons around its late-stage PC­SK9 de­vel­op­ment plans for in­clisir­an.

The Al­ny­lam part­ner said to­day that once the biotech com­pletes an ef­fort to sell off its in­fec­tious dis­ease group, the com­pa­ny — which had 410 staffers in Feb­ru­ary — will chop its re­main­ing work force down to a more af­ford­able group of less than 60 staffers.

Mean­well had al­ready put out word that he was look­ing for the best deal pos­si­ble for the in­fec­tious dis­ease busi­ness as the Par­si­pan­ny, NJ-based biotech ze­roes in on an LDL low­er­ing ther­a­py that has the po­ten­tial to over­take the lead­ers in the field: Re­gen­eron and Sanofi as well as their chief ri­val Am­gen.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.